Global Down Syndrome

Summer 2015

Issue link: https://viewer.e-digitaledition.com/i/545673

Contents of this Issue

Navigation

Page 18 of 31

CURRENT GUIDELINES FOR CELL-FREE FETAL DNA SCREENING Noninvasive cell-free fetal DNA screening is recommended only for women whose pregnancies are considered "high-risk." That group includes women who: • Are age 35 or older* • Have relatives with Down syndrome or have had previous children with a chromosomal condition • Had a first-trimester screen or quad screen that showed cause for concern are available to help families determine if a baby is likely to develop Down syndrome. Diagnostic tests provide the most definitive answer as to whether a baby has Down syndrome or another chromosomal condition. The two most common prenatal diagnostic tests used to detect Down syndrome are: • Amniocentesis, which is typically performed between the 15th and 22nd weeks of pregnancy and has an accuracy rate of 99.4 percent, according to the Cleveland Clinic. During an amniocentesis, physicians collect a small sample of amniotic fluid, which contains fetal cells that can be used to determine whether chromosomal conditions are present. • Chorionic villus sampling (CVS), which is usually performed between the 10th and 12th weeks of pregnancy. During CVS, doctors collect and analyze a sample of tissues known as chorionic villi, which are located on the placenta, to see if fetal cells contain an extra copy of chromosome 21. Like amniocentesis, CVS is nearly 100 percent accurate. While CVS and amniocentesis offer a clear picture of fetal health, the tests do pose a small risk of miscarriage, which occurs in less than 1 to 2 percent of pregnancies after a diagnostic test. Because of these risks, researchers have focused on developing less-invasive ways to test for Down syndrome. Prenatal screenings provide a glimpse at Down syndrome likelihood. These blood tests are safe and pose no risk of miscarriage, but they cannot give families a definitive diagnosis. The most common prenatal screenings are the first-trimester screen and the quad screen. The first-trimester screen consists of an ultrasound and a blood test that looks for certain proteins in the mother's blood that may indicate the baby has a chromosomal condition. The quad screening, which is performed early in the second trimester, is a blood test that looks for four specific proteins that may signal the presence of Down syndrome. If either of these tests suggests a mother may have a baby with Down syndrome, CVS or amniocentesis must be used to confirm the diagnosis. Noninvasive prenatal screenings simply help identify women whose babies are unlikely to have Down syndrome, so they can avoid further diagnostic testing. LOOKING TO THE FUTURE OF NONINVASIVE PRENATAL TESTING The medical community's ultimate goal is to develop a noninvasive screening test that offers the same level of accuracy as amniocentesis and CVS. With the arrival in 2011 of noninvasive prenatal screening using cell-free fetal DNA, some believe researchers may be getting closer to this objective. In cell-free fetal DNA testing, doctors analyze a mother's bloodstream for free fetal DNA, rather than the proteins analyzed in traditional prenatal screening tests. Those DNA, which come from the placenta, can signal the presence of Down syndrome (trisomy 21), as well as Patau syndrome (trisomy 13) and Edwards syndrome (trisomy 18). According to several studies, cell-free fetal DNA screening may be more accurate than first-trimester and quad screenings. A 2011 review published in Reviews in Obstetrics & Gynecology revealed the test is more than 99 percent accurate in women who have a high risk of giving birth to a baby with Down syndrome. This is an improvement over other screening options, which, the review notes, offer accuracy rates ranging from 75 to 96 percent. Further research has showed promise, but a 2015 study published in Fetal Diagnosis and Therapy revealed that the screening falls short of amniocentesis and CVS in terms of both accuracy and rates of false- positive results. At this time, the American Congress of Obstetricians and Gynecologists recommends physicians offer cell-free fetal DNA screening as an option only to women with high-risk pregnancies. Women with low-risk pregnancies should not receive the cell-free fetal DNA test. For more information about prenatal testing, download a digital copy of the Down Syndrome Prenatal Testing Pamphlet at downsyndrometest.org. Sources: acog.org; *Some testing companies define "high risk" as age 38 or older. GLOBALDOWNSYNDROME.ORG 19

Articles in this issue

Links on this page

Archives of this issue

view archives of Global Down Syndrome - Summer 2015